COMMUNIQUÉS West-GlobeNewswire

CorMedix Therapeutics Announces Share Repurchase Program
02/02/2026
BERKELEY HEIGHTS, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases [...]
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
02/02/2026
- Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron ® treatment to be well tolerated - ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: [...]
Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care
02/02/2026
Management to Engage with Global Clinical Research Leaders Ahead of Phase 2a Trial of Concussion Treatment Sarasota, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“the “Company”), a [...]
Sparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors
02/02/2026
BOSTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sparrow Pharmaceuticals , a targeted cardiometabolic therapeutics company, today announced the appointment of Carlo Incerti, M.D., to its Board of Directors, effective January 1 [...]
Spectral AI to Participate in National Burn Awareness Week 2026 February 1–7, 2026
02/02/2026
DALLAS, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment [...]
Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol “PLYX”
02/02/2026
PARAMUS, NJ, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (“Polaryx” or the “Company”) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease- [...]
Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation
02/02/2026
Peer-Reviewed Imaging Across Multiple Indications Validates Nexalin’s Ability to Modulate Deep Brain Networks, Differentiating It from other Superficial Neurostimulation Techniques HOUSTON, TX, Feb. 02, 2026 (GLOBE [...]
Cynet Appoints MacKenzie Brown as Vice President of Threat Intelligence Strategy
02/02/2026
Brown will be Cynet’s leading voice on adversary tactics to help partners understand and respond to threats faster BOSTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Cynet , the unified, AI-powered cybersecurity platform, has [...]
MAPS and Columbia University Partner on First-of-its-Kind Study of MDMA-Assisted Couples Therapy
02/02/2026
Anonymous survey with optional confidential interviews will document how practitioners facilitate MDMA-assisted couples therapy Findings to inform ethical guidelines, future clinical trial protocols, and policy [...]
Dandy Redefines the Chairside Experience With the Launch of Dandy Cart All-in-One Workstation
02/02/2026
Available at no additional cost, Dandy Cart turns scans into clear, visual stories, driving stronger case acceptance NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dandy , the fully digital dental lab, today announced the [...]
The Real Ironman Economy: How AI, Superfibers, and Defense Tech Could Theoretically Converge
02/02/2026
DENVER, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Recent reports that Palantir Technologies (NASDAQ: PLTR) has been tapped by President Trump to deploy AI systems to hunt fraud, likened in headlines to an AI “Ironman suit”, [...]
PacBio Completes Sale of Short-Read Sequencing Assets
02/02/2026
MENLO PARK, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the completion of the sale of select intellectual [...]
Johns Hopkins Health Plans Executive Elected Chair of Medicare Advantage Plan Alliance Compliance Forum
02/02/2026
Melissa Mohon to Lead National Organization Dedicated to Improving Regulatory Compliance and Quality Care for Medicare Beneficiaries HANOVER, Md., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Melissa L. Mohon, Executive Director [...]
Ringing in Your Ears? ASHA Shares Facts About a Common Yet Misunderstood Health Issue
02/02/2026
Association Stresses Importance of Prevention and Availability of Treatment for Tinnitus Awareness Week Rockville, Md., Feb. 02, 2026 (GLOBE NEWSWIRE) -- As many as one in three people globally have experienced tinnitus [...]
BrainCo’s Brain-Computer Interface Headband Supporting Social Skills Development in Children with Autism
02/02/2026
Somerville, MA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Improving social communication skills in children with autism has traditionally relied on structured teaching approaches and stable support environments. With the [...]
Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate
02/02/2026
Product is currently under review with the FDA Potential approval and launch mid-2026 DEER PARK, Ill., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative [...]
Communiqué de presse : Le venglustat de Sanofi a atteint tous les critères d'évaluation principaux dans une étude de phase 3 sur la maladie de Gaucher de type 3
02/02/2026
Le venglustat de Sanofi a atteint tous les critères d'évaluation principaux dans une étude de phase 3 sur la maladie de Gaucher de type 3 Dans l’étude de phase 3 LEAP2MONO, le venglustat, administré par voie orale une [...]
Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease
02/02/2026
Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease In the LEAP2MONO phase 3 study, venglustat, dosed orally once daily, demonstrated clinically meaningful efficacy in patients [...]
CROSSJECT announces initiation of coverage of its stock by Portzamparc (BNP Paribas Group)
02/02/2026
CROSSJECT announces initiation of coverage of its stock by Portzamparc (BNP Paribas Group) DIJON, France - February 2, 2026 (7:15 a.m. CET) – CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ) , the specialty pharmaceutical [...]

Pages